Cotrimoxazole. Rationale for re-examining its indications for use

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Therapeutics

Background:

• Trimethoprim was developed as a potentiator for sulphonamides, leading to the combination drug cotrimoxazole.
• Initial laboratory data suggested synergistic antimicrobial action and delayed resistance for cotrimoxazole.
• However, concerns exist regarding drug distribution, pathogen resistance, and clinical efficacy compared to monotherapy.

Purpose of the Study:

• To evaluate the clinical benefit and safety of cotrimoxazole compared to trimethoprim monotherapy.
• To assess the evidence for delayed resistance development with the combination therapy.
• To determine appropriate clinical indications for cotrimoxazole use.

Main Methods:

• Review of laboratory data on antimicrobial synergy and resistance.
• Analysis of clinical studies comparing trimethoprim alone versus cotrimoxazole for respiratory and urinary tract infections.
• Evaluation of adverse effect profiles and drug interactions for both treatment regimens.

Main Results:

• Clinical studies failed to demonstrate superior efficacy of cotrimoxazole over trimethoprim monotherapy for common infections.
• Evidence supporting the claim of delayed resistance development with cotrimoxazole use is unsubstantiated.
• Adverse effects like gastrointestinal issues and rashes appear less frequent with trimethoprim alone, while serious events may be more common with cotrimoxazole.

Conclusions:

• The clinical benefits of cotrimoxazole do not consistently outweigh the risks associated with using two drugs.
• The use of cotrimoxazole should be restricted to specific indications, such as Pneumocystis pneumonia, where its efficacy is established.
• Restricting cotrimoxazole use minimizes patient exposure to potential adverse effects and drug interactions without compromising therapeutic outcomes for most infections.